SOST and atherosclerosis: To the extent that genetically predicted lower lifelong exposure to sclerostin shares consequences with pharmacologic inhibition over 12 months, our results underscore the requirement for strategies to mitigate potential adverse effects of romosozumab treatment on atherosclerosis and its related risk factors.